Humuline Nph Kwikpen (Insulin Human (Rdna))

Humuline Nph Kwikpen is indicated for the long‑term management of blood glucose in adults and children with diabetes.

• Type 1 diabetes mellitus, used as basal (intermediate‑acting) insulin.
• Type 2 diabetes mellitus, often combined with oral agents or rapid‑acting insulin.
• Adjunct to diet and exercise to achieve individualized glycemic targets.
• Suitable for patients who require intermediate‑acting insulin for basal coverage.

• Insulin human (rDNA) in Humuline Nph Kwikpen binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s tyrosine kinase activity. This triggers intracellular signaling pathways that promote glucose uptake, glycogen synthesis, and lipogenesis while suppressing hepatic gluconeogenesis, thereby lowering circulating blood glucose concentrations.

Adverse reactions may occur with any insulin therapy. Patients should be aware of both frequent and less common events.

Common

• Hypoglycemia, especially if meals are missed or delayed.
• Injection‑site pain, redness, or swelling.
• Lipodystrophy (localized fat atrophy or hypertrophy).
• Transient weight gain.
• Mild allergic skin reactions such as itching or rash.

Serious

• Severe hypoglycemia with neurological impairment.
• Anaphylactic or systemic allergic reactions.
• Significant hypokalemia.
• Edema or fluid retention.
• Severe localized or generalized urticaria.

Humuline Nph Kwikpen requires careful monitoring and patient education to minimize risks.

• Verify blood glucose levels before each dose to avoid hypoglycemia.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced.
• Pregnant or breastfeeding individuals should consult a healthcare professional before use.
• Store the pen according to manufacturer instructions; do not use if the suspension appears discolored or contains clumps.
• Rotate injection sites to reduce lipodystrophy and improve absorption.

Certain medicines and substances can alter the action of insulin or increase the risk of adverse events.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• High‑dose beta‑blockers, which may mask hypoglycemia symptoms.
• MAO inhibitors combined with certain oral antidiabetic agents, increasing hypoglycemia risk.

Use with caution

• Oral hypoglycemic agents (e.g., sulfonylureas, meglitinides) that can potentiate insulin effects.
• Corticosteroids, which may raise blood glucose and require dose changes.
• Thiazide diuretics, which can affect potassium levels and glucose control.
• Alcohol, especially in excess, as it can cause unpredictable glucose fluctuations.